-
Jazz targets docs, consumers with branded Sunosi campaigns
fiercepharma
July 09, 2019
Jazz Pharmaceuticals started prepping the ground last year for its new sleep drug launch, and now it's official: The biopharma's Sunosi is rolling out this week with branded doctor advertising, a stepped-up sales force and digital direct-to-consumer pitch
-
Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies
En-CPhI.cn
June 27, 2019
Will Capitalize on Rapid Internationalization of Clinical Trials Between the US and China
-
Pfizer to Acquire Array BioPharma for $11.4B
contractpharma
June 18, 2019
Expands innovative biopharma business with multiple targeted investigational cancer therapies and adds a large portfolio of royalty-generating medicines.
-
Eurofins BioPharma Product Testing
europeanpharmaceuticalreview
June 17, 2019
Eurofins BioPharma Product Testing.
-
RedHill Biopharma Submits New Drug Application for Talicia for H. pylori Infection
drugs
May 17, 2019
RedHill Biopharma Submits New Drug Application for Talicia for H. pylori Infection.
-
Sekisui Invests $1.9M in Microbial Biopharma CDMO Business
contractpharma
May 17, 2019
New BioProcess Innovation Center in UK will be operational by the end of 2019.
-
Clinical Catch-up from Last Week: May 5-10
biospace
May 13, 2019
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
-
RedHill Biopharma enrols last patient in Phase II irritable bowel syndrome trial
europeanpharmaceuticalreview
May 07, 2019
RedHill Biopharma has enrolled the last patient in the Phase II study with Bekinda for the treatment of diarrhoea-predominant irritable bowel syndrome…
-
Growth in next-generation sequencing informatics market fuelled by big data
europeanpharmaceuticalreview
May 07, 2019
Report predicts strong demand from biopharma will encourage NGS informatics providers to deliver customised solutions...
-
Catalent Accelerates Formulation and Supply for MGB Biopharma Candidate
contractpharma
April 28, 2019
Catalent announced the initiation of Phase II clinical trials of MGB Biopharma’s lead candidate, MGB-BP-3, an orally-dosed drug targeting the eradication of Clostridium difficile-associated diarrhea (CDAD).